Completed PHASE2 INTERVENTIONAL 2-arm NCT00879606

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome

Sponsor: Altor BioScience

Conditions Acute Lung Injury Acute Respiratory Distress Syndrome Sepsis

Interventions ALT-836 Placebo

Updated 9 times since 2017 Last updated: Mar 20, 2015 Started: Apr 30, 2009 Primary completion: Oct 31, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Lung Injury and Acute Respiratory Distress Syndrome and is currently completed. Altor BioScience leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Altor BioScience
National Heart, Lung, and Blood Institute (NHLBI)

Data source: Altor BioScience

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Charlotte, United States , Chicago, United States , Greensboro, United States , Hazard, United States , Iowa City, United States , Kansas City, United States , Los Angeles, United States , Louisville, United States , New Haven, United States , New York, United States and 8 more locations